1414792-36-1

Basic information

• Product Name: 2-(4-((4-nitrobenzyl)thio)butyl)isoindoline-1,3-dione
• Synonyms: 2-(4-((4-nitrobenzyl)thio)butyl)isoindoline-1,3-dione
• CAS NO: 1414792-36-1
• Molecular Weight: 370.429
• Mol File: 1414792-36-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(4-((4-nitrobenzyl)thio)butyl)isoindoline-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-((4-nitrobenzyl)thio)butyl)isoindoline-1,3-dione(1414792-36-1)
• EPA Substance Registry System: 2-(4-((4-nitrobenzyl)thio)butyl)isoindoline-1,3-dione(1414792-36-1)

Safety Data

• Hazardous Substances Data: 1414792-36-1(Hazardous Substances Data)

Upstream product

• 118312-98-4 2-(4-mercaptobutyl)isoindoline-1,3-dione 
• 5394-18-3 2-(4-bromobutyl)isoindoline-1,3-dione 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 1074-82-4 potassium phtalimide 
• 396073-46-4 S-(4-(1,3-dioxoisoindolin-2-yl)butyl) ethanethioate 

Downstream Products

• 1414791-86-8 1-(((4-isothiocyanatobutyl)sulfinyl)methyl)-4-nitrobenzene 
• 1267489-66-6 C₁₁H₁₆N₂O₂S 
• 1414792-77-0 (4-isothiocyanatobutyl)(4-nitrobenzyl)sulfane 

Relevant articles and documents

Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control

A novel series of cyclin-dependent kinases (CDKs) inhibitors, which play critical roles in the cell cycle control and regulation of cell transcription, were synthesised. A systematic study of enzymatic and cellular assays led to the identification of compound X22 with a nanomolar potency against CDK4 and CDK9 and potent antiproliferative activities against a panel of tumour cell lines. X22 could induce cell cycle arrest and cell apoptosis in cancer cell lines. X22 dose-dependently inhibits signalling pathways downstream of CDKs in cancer cells. In vivo antitumor activity assays, oral administration of X22 led to significant tumour regression in mouse model without obvious toxicity. Superior anti-cancer efficacy in vitro and in vivo of X22 demonstrated combined depletion of cell cycle and transcriptional CDK all contributed to antitumor activity. Taken together, concomitant inhibition of cell cycle and transcriptional CDK activities provided valuable guide for further structural optimisation.

Thioether allyl isothiocyanate compounds, and preparation method and applications thereof

The invention provides a series of novel thioether allyl isothiocyanate compounds with a general structure disclosed in the invention, and a simple method used for rapid synthesis of the thioether allyl isothiocyanate compounds. According to the method, double-terminal halogen-substituted alkanes are taken as initial raw materials, are reacted with phthalimide potassium so as to introduce N atoms, are reacted with sodium hydrosulfide so as to produce mercaptan, and mercaptan is reacted with benzyl bromide or is reacted with a heterocyclic compound with sulfydryl so as to introduce the thioether structure, an obtained product is reacted with hydrazine hydrate so as to obtain a primary amine, and the primary amine is reacted with an alkali, carbon disulfide, and methylsufonyl chloride so as to prepare the thioether allyl isothiocyanate compounds with heterocyclic nitrogen structures. The method contains few steps; operation is simple; the obtained products can be easily purified; and yield is high. The series of novel thioether allyl isothiocyanate compounds possess obvious killing activity on tumor cells, and possess obvious killing activity on cervical carcinoma cells and lung cancer cells.